Misfolded proteinase K-resistant hyperphosphorylated α-synuclein in aged transgenic mice with locomotor deterioration and in human α-synucleinopathies

Journal of Clinical Investigation

Volumn 110, Issue 10, 2002, Pages 1429-1439

  Neumann, Manuela ^a   Kahle, Philipp J ^a   Giasson, Benoit I ^b   Ozmen, Laurence ^c   Borroni, Edilio ^c   Spooren, Will ^c   Müller, Veronika ^a   Odoy, Sabine ^a   Fujiwara, Hideo ^d   Hasegawa, Masato ^d   Iwatsubo, Takeshi ^d   Trojanowski, John Q ^b   Kretzschmar, Hans A ^a   Haass, Christian ^a  

^a UNIVERSITY OF MUNICH   (Germany)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c F HOFFMANN LA ROCHE LTD   (Switzerland)

^d UNIVERSITY OF TOKYO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN; DIRECT YELLOW 7; MONOCLONAL ANTIBODY; PROTEINASE K; THIOFLAVINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY SPECIFICITY; ARGYROPHILIA; ARTICLE; ASTROCYTOSIS; BRAIN STEM; CONTROLLED STUDY; HOMOZYGOSITY; HUMAN; HUMAN TISSUE; LOCOMOTION; MOUSE; NEURITIS; NEUROPATHOLOGY; NONHUMAN; OXIDATION; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN FOLDING; PROTEIN MODIFICATION; PROTEIN PHOSPHORYLATION; SPINAL CORD; TRANSGENIC MOUSE;

ALPHA-SYNUCLEIN; ANIMALS; BRAIN; DRUG RESISTANCE; ENDOPEPTIDASE K; FEMALE; GENE DOSAGE; HUMANS; LEWY BODY DISEASE; LOCOMOTION; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; NERVE TISSUE PROTEINS; NEURODEGENERATIVE DISEASES; PHOSPHORYLATION; PROTEIN FOLDING; SYNUCLEINS;

EID: 0036855635     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI200215777     Document Type: Article

References (52)

1. Goedert, M. 2001 Alpha-synuclein and neurodegenerative diseases. Nat. Rev. Neurosci. 2:492-501.
2. Abeliovich, A., et al. 2000. Mice lacking α-synuclein display functional deficits in the nigrostriatal dopamine system. Neuron. 25:239-252.
3. Murphy, D.D., Rueter, S.M., Trojanowski, I.Q., and Lee, V.M.-Y. 2000. Synucleins are developmentally expressed, and α-synuclein regulates the size of the presynaptic vesicular pool in primary hippocampal neurons. J. Neurosci. 20:3214-3220.
4. Polymeropoulos, M.H., et al. 1997. Mutation in the α-synuclein gene identified in families with Parkinson's disease. Science. 276:2045-2047.
5. Krüger, R., et al. 1998. Ala30Pro mutation in the gene encoding α-synuclein in Parkinson's disease. Nat. Genet. 18:106-108.
6. Spillantini, M.G., et al. 1997. α-synuclein in Lewy bodies. Nature. 388:839-840.
7. Takeda, A., et al. 1998. Abnormal accumulation of NACP/α-synuclein in neurodegenerative disorders. Am. J. Pathol. 152:367-372.
8. Arawaka, S., Saito, Y., Murayama, S., and Mori, H. 1998. Lewy body in neurodegeneration with brain iron accumulation type 1 is immunoreactive for α-synuclein. Neurology. 51:887-889.
9. Arai, K., Kato, N., Kashiwado, K., and Hattori, T. 2000. Pure autonomic failure in association with human α-synucleinopathy. Neurosci. Lett. 296:171-173.
10. Dickson, D.W., Lin, W., Liu, W.K., and Yen, S.H. 1999. Multiple system atrophy: A sporadic synucleinopathy. Brain Pathol. 9:721-732.
11. Okochi, M., et al. 2000. Constitutive phosphorylation of the Parkinson's disease associated α-synuclein. J. Biol. Chem. 275:390-397.
12. Fujiwara, H., et al. 2002. α-synuclein is phosphorylated in synucleinopathy lesions. Nat. Cell Biol. 4:160-164.
13. Conway, K.A., Harper, J.D., and Lansbury, P.T. 1998. Accelerated in vitro fibril formation by a mutant α-synuclein linked to early-onset Parkinson disease. Nat. Med. 4:1318-1320.
14. Narhi, L., et al. 1999. Both familial Parkinson's disease mutations accelerate α-synuclein aggregation. J. Biol. Chem. 274:9843-9846.
15. Hashimoto, M., et al. 1999. Oxidative stress induces amyloid-like aggregate formation of NACP/α-synuclein in vitro. Neuroreport. 10:717-721.
16. Souza, J.M., Giasson, B.I., Chen, Q., Lee, V.M.-Y., and Ischiropoulos, H. 2000. Dityrosine cross-linking promotes formation of stable α-synuclein polymers. Implication of nitrative and oxidative stress in the pathogenesis of neurodegenerative synucleinopathies. J. Biol. Chem. 275:18344-18349.
17. Conway, K.A., Harper, J.D., and Lansbury, P.T., Jr. 2000. Fibrils formed in vitro from α-synuclein and two mutant forms linked to Parkinson's disease are typical amyloid. Biochemistry. 39:2552-2563.
18. Giasson, B.I., Murray, I.V.J., Trojanowski, J.Q. and Lee, V.M.-Y. 2001. A hydrophobic stretch of 12 amino acid residues in the middle of α-synuclein is essential for filament assembly. J. Biol. Chem. 276:2380-2386.
19. Miake, H., Mizusawa, H., Iwasubo, T., and Hasegawa, M. 2002. Biochemical characterization of the core structure of α-synuclein filaments. J. Biol. Chem. 277:19213-19219.
20. Forloni, G. 1996. Neurotoxicicy of β-amyloid and prion peptides. Curr. Opin. Neurol. 9:492-500.
21. Feany, M.B., and Bender, W.W. 2000. A Drosophila model of Parkinson's disease. Nature. 404:394-398.
22. Auluck, P.K., Chan, H.Y.E., Trojanowski, J.Q., Lee, V.M.-Y., and Bonini, N.M. 2002. Chaperone suppression of α-synuclein toxicity in a Drosophila model for Parkinson's disease. Science. 295:865-868.
23. Masliah, E., et al. 2000. Dopaminergic loss and inclusion body formation in a-synuclein mice: Implications for neurodegenerative disorders. Science. 287:1265-1269.
24. van der Putten, H., et al. 2000. Neuropathology in mice expressing human α-synuclein. J. Neurosci. 20:6021-6029.
25. Kahle, P.J., et al. 2000. Subcellular localization of wild-type and Parkinson's disease-associated mutant α-synuclein in human and transgenic mouse brain. J. Neurosci. 20:6365-6373.
26. Kahle, P.J., et al. 2001. Selective insolubility of α-synuclein in human Lewy body diseases is recapitulated in a transgenic mouse model. Am. J. Pathol. 159:2215-2225.
27. Masliah, E., et al. 2001. β-amyloid peptides enhance ct-synuclein accumulation and neuronal deficits in a transgenic mouse model linking Alzheimer's disease and Parkinson's disease. Proc. Natl. Acad. Sci. USA. 98:12245-12250.
28. Hashimoto, M., Rockenstein, E., Mante, M., Mallory, M., and Masliah, E. 2001. β-synuclein inhibits α-synuclein aggregation. A possible role as an anti-Parkinsonian factor. Neuron. 32:213-223.
29. Trenkwalder, C., et al. 1995. Starnberg trial on epidemiology of Parkinsonism and hypertension in the elderly. Prevalence of Parkinson's disease and related disorders assessed by a door-to-door survey of inhabitants older than 65 years. Arch. Neurol. 52:1017-1022.
30. Giasson, B.I., et al. 2000. Oxidative damage linked to neurodegeneration by selective α-synuclein nitration in synucleinopathy lesions. Science. 290:985-989.
31. Sc early in the incubation time in prion diseases. Am. J. Pathol. 156:51-56.
32. Specht, C.G., and Schoepfer, R. 2001. Deletion of the α-synuclein locus in a subpopulation of C57BL/6J inbred mice. BMC Neurosci. 2:11.
33. Da Prada, M., et al. 1988. Neurochemical profile of moclobemide, a short-acting and reversible inhibitor of monoamine oxidase type A. Pharmacol. Exp. Ther. 248:400-414.
34. Taraboulos, A., et al. 1992. Regional mapping of prion proteins in brain. Proc. Natl. Acad. Sci. USA. 89:7620-7624.
35. McKeith, I.G., et al. 1996. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): Report of the consortium on DLB international workshop. Neurology. 47:1113-1124.
36. Neumann, M., et al. 2000. α-synuclein accumulation in a case of neurodegeneration with brain iron accumulation type 1 (NBIA-1, formerly Hallervorden-Spatz syndrome) with widespread cortical and brainstem-type Lewy bodies. Acta Neuropathol. 100:568-574.
37. Del Tredici, K., Rüb, U., de Vos, R.A.I., Bohl, J.R.E., and Braak, H. 2002. Where does Parkinson disease pathology begin in the brain? J. Neuropathol. Exp. Neurol. 61:413-426.
38. Arima, K., et al. 1998. Immunoelectron-microscepic demonstration of NACP/α-synuclein-epitopes on the filamentous component of Lewy bodies in Parkinson's disease and in dementia with Lewy bodies. Brain Res. 808:93-100.
39. Giasson, B.I., et al. 2002. Neuronal α-synucleinopathy with severe movement disorder in mice expressing A53T human α-synuclein. Neuron. 34:521-533.
40. Ishihara, T., et al. 1999. Age-dependent emergence and progression of a tauopathy in transgenic mice overexpressing the shortest human tau isoform. Neuron. 24:751-762.
41. Lewis, J., et al. 2000. Neurofibrillary tangles, amyotrophy and progressive motor disturbance in mice expressing mutant (P30I) tau protein. Nat. Genet. 25:402-405.
42. Giasson, B.I., Uryu, K., Trojanowski, J.Q., and Lee, V.M.-Y. 1999. Mutant and wild type human α-synucleins assemble into elongated filaments with distinct morphologies in vitro. J. Biol. Chem. 274:7619-7622.
43. Spillantini, M.G., Crowther, R.A., Jakes, R., Hasegawa, M., and Goedert, M. 1998. α-synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with Lewy bodies. Proc. Natl. Acad. Sci. USA. 95:6469-6473.
44. Takeda, A., et al. 1998. Abnormal distribution of the non-Aβ component of Alzheimer's disease amyloid precursor/α-synuclein in Lewy body disease as revealed by proteinase K and formic acid pretreatment. Lab. Invest. 78:1169-1177.
45. Tompkins, M.M., and Hill, W.D. 1997. Contribution of somal Lewy bodies to neuronal death. Brain Res. 775:24-29.
46. Rockenstein, E., et al. 2001. Altered expression of the synuclein family mRNA in Lewy body and Alzheimer's disease. Brain Res. 914:48-56.
47. Pronin, A.N., Morris, A.J., Surguchov, A., and Benovic, J.L. 2000. Synucleins are a novel class of substrates for G protein-coupled receptor kinases. J. Biol. Chem. 275:26515-26522.
48. Lee, M.K., et al. 2002. Human α-synuclein-harboring familial Parkinson's disease-linked Ala-53 → Thr mutation causes neurodegenerative disease with α-synuclein aggregation in transgenic mice. Proc. Natl. Acad. Sci. USA. 99:8968-8973.
49. Rathke-Hartlieb, S., et al. 2001. Sensitivity to MPTP is not increased in Parkinson's disease-associated mutant α-synuclein transgenic mice. J. Neurochem. 77:1181-1184.
50. Matsuoka, Y., et al. 2001. Lack of nigral pathology in transgenic mice expressing human α-synuclein driven by the tyrosine hydroxylase promoter. Neurobiol. Dis. 8:535-539.
51. Klein, R.L., King, M.A., Hamby, M.E., and Meyer, E.M. 2002. Dopaminergic cell loss induced by human A30P α-synuclein gene transfer to the rat substantia nigra. Hum. Gene Ther. 13:605-612.
52. Kirik, D., et al. 2002. Parkinson-like neurodegeneration induced by targeted overexpression of α-synuclein in the nigrostriatal system. J. Neurosci. 22:2780-2791.